Celcuity Inc. (CELC) |
| 88.44 -4.8 (-5.15%) 08-28 16:00 |
| Open: | 91.9 |
| High: | 92.41 |
| Low: | 88.225 |
| Volume: | 610,267 |
| Market Cap: | 4,313(M) |
| PE Ratio: | -20.57 |
| Exchange: | NASDAQ |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 112.31 |
| Resistance 1: | 96.16 |
| Pivot price: | 91.52 |
| Support 1: | 85.31 |
| Support 2: | 78.60 |
| 52w High: | 151.02 |
| 52w Low: | 44.42 |
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Financials
| EPS | 0.000 |
| Book Value | -4.300 |
| PEG Ratio | 169.12 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | -25.8 |
Company news
Wed, 26 Aug 2026
Celcuity’s three-drug breast cancer treatment cut progression or death risk 50% vs. alpelisib - Stock Titan
Mon, 24 Aug 2026
Celcuity (CELC) Technicals: Finishes 2.93% Down at $90.79 in the Latest Reading; Levels: Price Remains Between $86.25 Support and $95.33 Resistance - Dividend Growth Stocks - vinanet.vn
Mon, 24 Aug 2026
How Investors May Respond To Celcuity (CELC) Deepening Losses As Gedatolisib Commercial Plans Advance - simplywall.st
Mon, 24 Aug 2026
Price to book forward of Celcuity Inc. – NASDAQ:CELC - TradingView
Sun, 16 Aug 2026
The Bull Case For Celcuity (CELC) Could Change Following Revtopik’s FDA Approval And NCCN Category 1 Status - simplywall.st
Sat, 15 Aug 2026
Is Celcuity (CELC) A Bargain As Losses Widen Ahead Of Its First Launch? - Yahoo Finance
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
